<div id="readability-page-1"><article>Highlighting Optimized Once-Daily Weight-Based Dosing and Clinically Meaningful Fatigue ImprovementSan Diego, California--(Newsfile Corp. - January 23, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) (&#34;Thiogenesis&#34; or the &#34;Company&#34;), a clinical-stage biotechnology company developing next-generation thiol-based prodrugs for rare mitochondrial and pediatric diseases, today announced the presentation of interim data from its Phase 2 (EU) clinical study of TTI-0102 in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) at Mitocon 2026 - a leading international conference dedicated to mitochondrial medicine being held in Pisa, Italy.The poster, titled &#34;TTI-0102 in MELAS: PK/PD Results from a Phase 2 Study - Preliminary Evidence of Safety and Efficacy in Mitochondrial Disease,&#34; was presented on January 23 as part of Mitocon's Late-Breaking News session, a distinction reserved for data of high scientific and clinical relevance selected by the conference's Scientific Committee.Phase 2 (EU) MELAS - Study HighlightsThe randomized, single-blind, high fixed-dose, placebo-controlled exploratory Phase 2 (EU) study enrolled nine (n=9) patients with genetically confirmed MELAS, a devastating mitochondrial disorder with limited therapeutic options. Results presented at Mitocon demonstrated that weight-based dosing is critical to achieving optimal exposure and tolerability, consistent with long-standing clinical experience using cysteamine in concentrations comparable to approved formulations (Cystagon® or Procysbi®) in cystinosis.Key clinical, pharmacokinetic, and pharmacodynamic findings included:Clinical Outcome (Fatigue):<ul><li>Statistically significant improvement in patient-reported fatigue as measured by the total score of Modified Fatigue Impact Scale (MFIS)</li><li>At an average dose of approximately 60 mg/kg/day, TTI-0102-treated patients demonstrated a mean reduction of up to 10% in total MFIS score compared to placebo (p &lt; 0.001)</li><li>Fatigue is a cardinal and functionally limiting symptom affecting patients with mitochondrial disease</li></ul>Pharmacokinetics (PK):<ul><li>Sustained 24-hour cysteamine exposure achieved with once-daily, weight-based dosing</li><li>Identification of an optimal dose of approximately 60 ± 5 mg/kg of TTI-0102 to achieve target exposure</li><li>Lower peak plasma cysteamine concentrations (Cmax) at this dose compared with fixed dosing and approved cysteamine formulations, supporting improved gastrointestinal tolerability</li></ul>Pharmacodynamics (PD):<ul><li>Increased plasma pyruvate without lactate elevation, suggesting enhanced glycolytic flux; a metabolic state in which glucose is more efficiently converted into usable cellular energy rather than diverted into lactate production, consistent with improved mitochondrial energy handling </li><li>Decreased plasma tryptophan, potentially reducing oxidative stress associated with neurotoxic kynurenine pathway metabolites</li><li>These pharmacodynamic effects were dose-dependent, negligible below 40 mg/kg/day, optimal at approximately 60 mg/kg/day, and slightly reduced at higher doses</li></ul>Taken together, these pharmacodynamic findings are consistent with reduced oxidative stress and improved cellular energy metabolism, supporting the proposed mechanism of TTI-0102 in mitochondrial disease, based on thiol-disulfide exchange equilibrium, and providing biological rationale for the observed clinical improvement in fatigue.The study further demonstrated that fixed dosing resulted in gastrointestinal adverse events and treatment discontinuations in lower-weight patients, whereas weight-adjusted dosing mitigated these effects, supporting its use in future clinical trials. Weight-based dosing at 60 ± 5 mg/kg TTI-0102 (~26 mg/kg cysteamine base equivalent) achieved sustained 24-hour cysteamine exposure with half the daily dose of Cystagon® or Procysbi® administered to patients with cystinosis, and lower peak concentrations. &#34;The results presented at Mitocon confirm that TTI-0102 achieves meaningful biological and clinical proof-of-concept in MELAS when administered using appropriate weight-based dosing,&#34; said Patrice Rioux, M.D., Ph.D., Chief Executive Officer and Co-Founder of Thiogenesis. &#34;Notably, the statistically significant improvement in fatigue measured by MFIS is highly relevant, as fatigue represents a core functional component captured within the comprehensive MM-COAST outcome framework that will be used in our upcoming Phase 2a study in Leigh syndrome spectrum. Together with a well-characterized pharmacokinetic and pharmacodynamic profile, these findings directly inform the design of our Leigh program.&#34;About MFISThe Modified Fatigue Impact Scale (MFIS) is a validated, patient-reported outcome measure widely used in neurological and mitochondrial disorders to assess the impact of fatigue on physical, cognitive, and psychosocial functioning. Fatigue affects an estimated 71-100% of patients with mitochondrial disease and is frequently reported as one of the most debilitating symptoms. MFIS has been shown to be sensitive to clinically meaningful change and is considered an appropriate endpoint for evaluating therapeutic benefit in mitochondrial disorders.About MitoconMitocon - Insieme per lo studio e la cura delle malattie mitocondriali OdV - is Italy's leading patient advocacy organization dedicated to mitochondrial diseases. Mitocon supports research, education, and collaboration among clinicians, scientists, and patient communities, and its annual international conference is widely recognized as a premier forum for the presentation of emerging scientific and clinical advances in mitochondrial medicine.About MELASMitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) is a rare, inherited mitochondrial disorder most caused by a mutation in mitochondrial DNA (m.3243A&gt;G). Symptoms include seizures, muscle weakness, fatigue, headaches, and stroke-like episodes. Oxidative stress and impaired mitochondrial energy metabolism are key contributors to disease progression. MELAS affects an estimated 4.1 per 100,000 individuals worldwide and is considered an orphan disease.About Leigh Syndrome SpectrumLeigh syndrome spectrum is a rare, inherited mitochondrial disorder typically diagnosed in infancy or early childhood and affecting approximately 1 in 40,000 live births. The disease is characterized by progressive neurological decline, developmental regression, respiratory dysfunction, and seizures. There are currently no approved therapies for Leigh syndrome spectrum.About TTI-0102TTI-0102 is Thiogenesis' lead product candidate and a next-generation cysteamine-based prodrug designed to overcome limitations of first-generation thiol therapies, including short half-life, gastrointestinal side effects, and dosing constraints. Through controlled metabolic activation, TTI-0102 enables sustained cysteamine exposure with the potential for improved tolerability and simplified dosing. The compound is being evaluated across multiple indications associated with mitochondrial dysfunction and oxidative stress, including MELAS, Leigh syndrome spectrum, and nephropathic cystinosis.About Thiogenesis TherapeuticsThiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The Company is developing sulfur-containing prodrugs designed to act as precursors to previously approved thiol-active compounds, with the potential to address serious pediatric diseases with significant unmet medical need. Thiogenesis' lead program, TTI-0102, is being evaluated in MELAS, an IND-cleared Phase 2a study planned in Leigh syndrome spectrum, and a Phase 3 study planned in nephropathic cystinosis.For further information, please contact: Brook Riggins, CFA Director, and CFO Email: info@thiogenesis.com Tel.: (888) 223-9165 Forward-Looking Statements This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as &#34;forward- looking statements&#34;) within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions, or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTC Markets Group Inc. (OTCQX: OTCM) accepts responsibility for the adequacy or accuracy of this news release. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281290<img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/281290/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/281290/375"/></article></div>

DNTH

TTRX

KTTAW

KTTA

NBSE.ESC

Thiogenesis Therapeutics presented interim data from its Phase 2 (EU) study of TTI-0102 for MELAS at Mitocon 2026. The study showed significant improvement in fatigue, with a 10% reduction in MFIS scores for treated patients. Weight-based dosing of approximately 60 mg/kg/day achieved optimal exposure and tolerability, supporting its use in future trials. The findings indicate TTI-0102's potential in improving mitochondrial energy metabolism and reducing oxidative stress, with implications for upcoming studies in related conditions.

Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026 | TTIPF Stock News